BACKGROUND: Chemoprevention is an option for women who are at increased risk of breast cancer (five year risk ≥1.7%). It is uncertain, however, how often women accept and complete five years of therapy and whether clinical or demographic factors predict completion. METHODS: Medical records were abstracted for 219 women whose five year risk of breast cancer was ≥1.7% and who were offered chemoprevention while attending a high risk breast clinic at the Moffitt Cancer Center. We examined the likelihood of accepting chemoprevention and completing five years of therapy, and potential clinical and demographic predictors of these outcomes, using multivariable logistic regression and survival analysis models. RESULTS: There were 118/219 women (54.4%) who accepted a recommendation for chemoprevention and began therapy. The likelihood of accepting chemoprevention was associated with lifetime breast cancer risk and was higher for women with specific high risk conditions (lobular carcinoma in situ and atypical ductal hyperplasia). Women with osteoporosis and those that consumed alcohol were also more likely to accept medication. There were 58/118 (49.2%) women who stopped medication at least temporarily after starting therapy. Based on survival curves, an estimated 60% of women who begin chemoprevention will complete five years of therapy. CONCLUSIONS: A substantial percentage of women at increased risk of breast cancer will decline chemoprevention and among those that accept therapy, approximately 40% will not be able to complete five years of therapy because of side effects.
BACKGROUND: Chemoprevention is an option for women who are at increased risk of breast cancer (five year risk ≥1.7%). It is uncertain, however, how often women accept and complete five years of therapy and whether clinical or demographic factors predict completion. METHODS: Medical records were abstracted for 219 women whose five year risk of breast cancer was ≥1.7% and who were offered chemoprevention while attending a high risk breast clinic at the Moffitt Cancer Center. We examined the likelihood of accepting chemoprevention and completing five years of therapy, and potential clinical and demographic predictors of these outcomes, using multivariable logistic regression and survival analysis models. RESULTS: There were 118/219 women (54.4%) who accepted a recommendation for chemoprevention and began therapy. The likelihood of accepting chemoprevention was associated with lifetime breast cancer risk and was higher for women with specific high risk conditions (lobular carcinoma in situ and atypical ductal hyperplasia). Women with osteoporosis and those that consumed alcohol were also more likely to accept medication. There were 58/118 (49.2%) women who stopped medication at least temporarily after starting therapy. Based on survival curves, an estimated 60% of women who begin chemoprevention will complete five years of therapy. CONCLUSIONS: A substantial percentage of women at increased risk of breast cancer will decline chemoprevention and among those that accept therapy, approximately 40% will not be able to complete five years of therapy because of side effects.
Authors: Paul E Goss; James N Ingle; José E Alés-Martínez; Angela M Cheung; Rowan T Chlebowski; Jean Wactawski-Wende; Anne McTiernan; John Robbins; Karen C Johnson; Lisa W Martin; Eric Winquist; Gloria E Sarto; Judy E Garber; Carol J Fabian; Pascal Pujol; Elizabeth Maunsell; Patricia Farmer; Karen A Gelmon; Dongsheng Tu; Harriet Richardson Journal: N Engl J Med Date: 2011-06-04 Impact factor: 91.245
Authors: Victor G Vogel; Joseph P Costantino; D Lawrence Wickerham; Walter M Cronin; Reena S Cecchini; James N Atkins; Therese B Bevers; Louis Fehrenbacher; Eduardo R Pajon; James L Wade; André Robidoux; Richard G Margolese; Joan James; Scott M Lippman; Carolyn D Runowicz; Patricia A Ganz; Steven E Reis; Worta McCaskill-Stevens; Leslie G Ford; V Craig Jordan; Norman Wolmark Journal: JAMA Date: 2006-06-05 Impact factor: 56.272
Authors: Erika A Waters; Timothy S McNeel; Worta McCaskill Stevens; Andrew N Freedman Journal: Breast Cancer Res Treat Date: 2012-05-24 Impact factor: 4.872
Authors: Elizabeth Barrett-Connor; Lori Mosca; Peter Collins; Mary Jane Geiger; Deborah Grady; Marcel Kornitzer; Michelle A McNabb; Nanette K Wenger Journal: N Engl J Med Date: 2006-07-13 Impact factor: 91.245
Authors: J P Costantino; M H Gail; D Pee; S Anderson; C K Redmond; J Benichou; H S Wieand Journal: J Natl Cancer Inst Date: 1999-09-15 Impact factor: 13.506
Authors: Vanessa K Goldenberg; Victoria L Seewaldt; Victoria Scott; Gregory R Bean; Gloria Broadwater; Carol Fabian; Bruce Kimler; Carola Zalles; Isaac M Lipkus Journal: Cancer Epidemiol Biomarkers Prev Date: 2007-05 Impact factor: 4.254
Authors: Karla Kerlikowske; Charlotte C Gard; Brian L Sprague; Jeffrey A Tice; Diana L Miglioretti Journal: Cancer Epidemiol Biomarkers Prev Date: 2015-03-30 Impact factor: 4.254
Authors: Jennifer G McIntosh; Jesse Minshall; Sibel Saya; Adrian Bickerstaffe; Nadira Hewabandu; Ashleigh Qama; Jon D Emery Journal: Br J Gen Pract Date: 2019-11-28 Impact factor: 5.386
Authors: Tari A King; Melissa Pilewskie; Shirin Muhsen; Sujata Patil; Starr K Mautner; Anna Park; Sabine Oskar; Elena Guerini-Rocco; Camilla Boafo; Jessica C Gooch; Marina De Brot; Jorge S Reis-Filho; Mary Morrogh; Victor P Andrade; Rita A Sakr; Monica Morrow Journal: J Clin Oncol Date: 2015-09-14 Impact factor: 44.544
Authors: Goli Samimi; Brandy M Heckman-Stoddard; Shelley S Kay; Bonny Bloodgood; Kisha I Coa; Jennifer L Robinson; Bethany Tennant; Leslie G Ford; Eva Szabo; Lori Minasian Journal: Cancer Prev Res (Phila) Date: 2019-03-01
Authors: Stephanie R Land; Farzana L Walcott; Qing Liu; D Lawrence Wickerham; Joseph P Costantino; Patricia A Ganz Journal: J Natl Cancer Inst Date: 2015-11-27 Impact factor: 13.506
Authors: Haley Manley; Simukayi Mutasa; Peter Chang; Elise Desperito; Katherine Crew; Richard Ha Journal: Clin Breast Cancer Date: 2020-11-17 Impact factor: 3.225